Key result
Review examines pathogenesis, imaging, and clinical implications of LV fibrosis in AF and HFrEF.
Why the study?
While the role of atrial fibrosis has been described, the impact of left ventricular myocardial fibrosis in concurrent atrial fibrillation and heart failure remains less clearly defined.
This comprehensive review highlights the clinical implications of left ventricular fibrosis in managing atrial fibrillation among patients with heart failure with reduced ejection fraction.
Answers are grounded in this paper and cite their sources.
May inform fibrosis assessment in AF with HFrEF; leaves open optimal imaging and targeted therapies pending prospective validation.
Atrial fibrillation (AF) and heart failure commonly coexist and their concurrent presence is linked to worse clinical outcomes. While the role of atrial fibrosis in shaping the atrial substrate and influencing post-ablation success has been described, the impact of left ventricular (LV) myocardial fibrosis remains less clearly defined. This contemporary review explores the pathogenesis of LV fibrosis, imaging modalities for its detection and the clinical implications of ventricular fibrosis for AF management in the setting of heart failure with reduced ejection fraction. We also highlight key knowledge gaps and outline priorities for future research to refine risk stratification and guide therapy.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) conducted a review in Atrial fibrillation and heart failure with reduced ejection fraction. Left ventricular myocardial fibrosis was evaluated. This comprehensive review explores the pathogenesis, imaging detection, and clinical implications of left ventricular myocardial fibrosis in atrial fibrillation and heart failure with reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: